Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Recruiting Observational Study
Emphysema
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 85
Sex
Any
Study type
Observational
Participants needed
45 (estimated)
Sponsor
McMaster University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria (COPD): * ≥40 years of age * Current or ex-smokers with a \>10 pack year smoking history * Have a post-bronchodilator forced expired volume in 1 second (FEV1)/forced expired vital capacity (FVC) ratio of \<70% and a post-bronchodilator FEV1 value from ≥30% predicted (GOLD 1, 2 an…
Contacts

Sarah Svenningsen, PhD

905-522-1155

svennins@mcmaster.ca

CONTACT

Melanie Kjarsgaard

905-522-1155

mkjarsga@stjoes.ca

CONTACT